Small Cell Lung Cancer

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.

In an interview with Targeted Oncology, Ariel Lopez-Chavez, MD, discussed recent developments in the small cell lung cancer space.

Ariel Lopez-Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.

Robert L. Ferris, MD, PhD, highlights groundbreaking advancements presented at the recent World Congress on Lung Cancer held in San Diego, California.

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.

The 0.09 mg/kg dose group of the phase 1 dose-escalation portion of the Acclaim-3 study in extensive-stage small cell lung cancer is completed.

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and progression-free survival in extensive-stage small cell lung cancer.

With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David R. Spigel, MD, is optimistic about the future of small cell lung cancer treatment.

Missak Haigentz, MD, discussed the implications and next steps of the ADRIATIC study in patients with limited-stage small cell lung cancer.

The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

During an in-person Community Case Forum event, Ticiana Leal, MD, discussed the trials of lurbinectedin and tarlatalamb as therapy for previously treated small cell lung cancer.

Backed by the phase 1 ARTEMIS-001 trial, the FDA has granted GSK5764227 a breakthrough therapy designation for the treatment of extensive-stage small cell lung cancer.

Durvalumab was also granted breakthrough therapy designation for the treatment of patients with limited-stage small cell lung cancer.

KeyVibe-008, a phase 3 study investigating the combination of vibostolimab and pembrolizumab in small cell lung cancer, did not show an improvement in overall survival.

Ayal Aizer, MD, MHS, discussed the changing treatment paradigms of treatment of brain metastases in patients with small cell lung cancer.

The phase 3 IDeate-Lung02 study has dosed its first patient with small cell lung cancer with the investigational antibody-drug conjugate infinatamab deruxtecan.

Small cell lung cancer poses a significant challenge across the world, particularly in low-middle-income countries where it is often associated with poor outcomes.

7MW3711, an innovative antibody-drug conjugate targeting B7-H3, has been granted an orphan drug designation by the FDA for treating small cell lung cancer.

In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.